Literature DB >> 2418114

Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis.

R E Baughn, M C McNeely, J L Jorizzo, D M Musher.   

Abstract

Sera from patients with secondary syphilis were evaluated for abnormal levels of circulating immune complexes (IC), immunoglobulins (Ig), and complement components. Clq-solid-phase assays (Clq-SPA) that made use of monoclonal and polyclonal antibodies directed against IgG subclasses indicated that human IC were composed primarily of IgG3 and IgG1; these findings appeared consistent with subclass profile responses of electrophoretically transferred blots (Western blots) of Treponema pallidum reacted with syphilitic sera. Complexes were isolated from reactive sera by polyethylene glycol precipitation followed by either anti-Clq column chromatography or protein A-Sepharose chromatography. Although qualitative and quantitative differences were noted, all purified materials contained a treponemal polypeptide antigen with a m.w. of approximately 87,000. Subsequent analysis of this polypeptide, which was also present in purified IC from rabbits with experimental syphilis, suggests that it may represent the fibronectin receptor of the organism. The 76,000 and 66,000 materials, earlier identified in purified rabbit IC, appeared to represent C-terminal degradation products of fibronectin presumably of host origin, rather than treponemal antigens. Although fibronectin binds avidly to Clq and could represent a co-precipitable contaminant throughout the isolation procedure, anti-fibronectin antibodies in the sera of patients detectable by radioimmunoassay and the present of antibodies to 76,000 and 66,000 dalton fibronectin fragments in the globulin fractions of disassociated complexes argues against such a conclusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418114

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Epitope mapping of B-cell determinants on the 15-kilodalton lipoprotein of Treponema pallidum (Tpp15) with synthetic peptides.

Authors:  R E Baughn; M Demecs; L H Taber; D M Musher
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Secondary syphilitic lesions.

Authors:  Robert E Baughn; Daniel M Musher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Secondary syphilis presenting as nephrotic syndrome.

Authors:  G J Magarian; C Marr
Journal:  West J Med       Date:  1992-06

4.  IgM rheumatoid factor in congenital syphilis: associations with clinical and laboratory findings.

Authors:  M P Meyer; D W Beatty
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

5.  Plasma fibronectin concentrations in patients with human immunodeficiency virus infection.

Authors:  D Torre; M Issi; C Sampietro; G P Fiori; G Chelazzi; G Ferraro
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

6.  Experimental congenital syphilis: guinea pig model.

Authors:  K Wicher; R E Baughn; V Wicher; S Nakeeb
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

7.  Anti-Treponema pallidum IgM, IgA, and IgG subclass antibody responses after treatment in patients with syphilis at various stages: 1. Assessments by enzyme-linked immunosorbent assay.

Authors:  S Tanaka; T Suzuki
Journal:  Genitourin Med       Date:  1990-06

8.  Treponemal infection specifically enhances node T-cell regulation of macrophage activity.

Authors:  D R Tabor; O Bagasra; R F Jacobs
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

9.  Antibody-independent interactions of fibronectin, C1q, and human neutrophils with Treponema pallidum.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

10.  Enteric infection with an obligate intracellular parasite, Encephalitozoon cuniculi, in an experimental model.

Authors:  V Wicher; R E Baughn; C Fuentealba; J A Shadduck; F Abbruscato; K Wicher
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.